Search

Displaying results 7751 - 7760 of 9325 in total
  1. Drug

    Tretamine

    go.drugbank.com/drugs/DB14031
    Experimental

    Toxic alkylating agent used in industry; also as antineoplastic and research tool to produce chromosome aberrations and cancers.

    Synonyms: TEM
  2. Drug

    Agerafenib

    go.drugbank.com/drugs/DB15068
    Investigational

    Agerafenib is under investigation in clinical trial NCT03052569 (Expanded Access to RXDX-105 for Cancers With RET Alterations).

  3. Drug

    anti-OX40 antibody BMS 986178

    go.drugbank.com/drugs/DB15773
    Investigational

    A macrocyclic peptide (BMS-986189) with activity in binding and functional assays comparable to a PD-L1 antibody.

  4. Drug

    Izencitinib

    go.drugbank.com/drugs/DB16660
    Investigational

    Izencitinib is under investigation in clinical trial NCT03920254 (TD-1473 Long-term Safety (LTS) Ulcerative Colitis (UC) Study).

  5. Drug

    Trotabresib

    go.drugbank.com/drugs/DB17421
    Investigational

    Trotabresib is an oral, potent, and reversible inhibitor of the epigenetic target bromodomain and extra-terminal (BET) proteins.

  6. Drug

    OPC1

    go.drugbank.com/drugs/DB17944
    Experimental

    OPC1 is an oligodendrocyte progenitor cell therapy being investigated for the treatment of acute spinal cord injury.[L47082]

  7. Drug

    PMC-403

    go.drugbank.com/drugs/DB18132
    Investigational

    PMC-403 is a novel Tie2-activating antibody being investigated for the treatment of systemic capillary leak syndrome.

    Synonyms: a fully human monoclonal antibody that binds and activates the Tie2 receptor
  8. Drug

    NGN-101

    go.drugbank.com/drugs/DB18335
    Investigational

    NGN-101 is an adeno-associated virus serotype 9 vector with engineered transgene encoding the human CLN5 gene

  9. Drug

    AGTC-402

    go.drugbank.com/drugs/DB18433
    Investigational

    AGTC-402 is a recombinant adeno-associated virus vector expressing the cyclic nucleotide gated channel alpha subunit (CNGA3).

  10. Drug

    ECT204

    go.drugbank.com/drugs/DB18605
    Investigational

    ECT204 is an autologous T-cell therapy whereby T cells are genetically modified to target tumor-specific antigens.